commands study: efficacy & safety results and biomarker analysis
Published 1 year ago • 83 plays • Length 4:19Download video MP4
Download video MP3
Similar videos
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
7:30
updates from juliet: correlative analyses and clinical characteristics associated with efficacy
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:30
understanding the effect of other diseases on blood biomarker levels in ad
-
3:18
midiagnostics' complete blood count (cbc) - blood analysis for diagnosis and monitoring
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
5:45
how to interpret a cbc (complete blood count) (hematopathology & hematology with dr. jeanette ramos)
-
1:01
"clinical haematology" - out now!
-
1:34
are thrombotic risk and progression in et predictable?
-
16:11
hematology - complete blood count (cbc) - critical care labs
-
1:53
the detection and management of mnts following bcma-directed car-t therapy
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
1:03
late effect surveillance following allosct: the publication of new guidelines